JP2016506914A - 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド - Google Patents

骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド Download PDF

Info

Publication number
JP2016506914A
JP2016506914A JP2015553175A JP2015553175A JP2016506914A JP 2016506914 A JP2016506914 A JP 2016506914A JP 2015553175 A JP2015553175 A JP 2015553175A JP 2015553175 A JP2015553175 A JP 2015553175A JP 2016506914 A JP2016506914 A JP 2016506914A
Authority
JP
Japan
Prior art keywords
fgfr3
polypeptide
sfgfr3
treatment
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015553175A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016506914A5 (https=
Inventor
エルヴィール・グーズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Toulouse
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Toulouse III Paul Sabatier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Universite Toulouse III Paul Sabatier filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of JP2016506914A publication Critical patent/JP2016506914A/ja
Publication of JP2016506914A5 publication Critical patent/JP2016506914A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015553175A 2013-01-16 2013-01-16 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド Withdrawn JP2016506914A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2013/001480 WO2014111744A1 (en) 2013-01-16 2013-01-16 A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019149672A Division JP2020015733A (ja) 2019-08-19 2019-08-19 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド

Publications (2)

Publication Number Publication Date
JP2016506914A true JP2016506914A (ja) 2016-03-07
JP2016506914A5 JP2016506914A5 (https=) 2016-11-17

Family

ID=48289519

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015553175A Withdrawn JP2016506914A (ja) 2013-01-16 2013-01-16 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
JP2015553074A Withdrawn JP2016506912A (ja) 2013-01-16 2014-01-16 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
JP2019021752A Expired - Fee Related JP6995069B2 (ja) 2013-01-16 2019-02-08 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015553074A Withdrawn JP2016506912A (ja) 2013-01-16 2014-01-16 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
JP2019021752A Expired - Fee Related JP6995069B2 (ja) 2013-01-16 2019-02-08 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド

Country Status (19)

Country Link
US (5) US20150344855A1 (https=)
EP (2) EP2945967B1 (https=)
JP (3) JP2016506914A (https=)
KR (3) KR20160002681A (https=)
CN (1) CN105121464B (https=)
AU (2) AU2013373679A1 (https=)
CA (2) CA2898415A1 (https=)
DK (1) DK2945967T3 (https=)
EA (2) EA201591324A1 (https=)
ES (1) ES2796743T3 (https=)
HU (1) HUE049556T2 (https=)
IL (2) IL239810A0 (https=)
MX (2) MX372787B (https=)
PE (1) PE20151664A1 (https=)
PL (1) PL2945967T3 (https=)
PT (1) PT2945967T (https=)
SG (2) SG11201505488XA (https=)
SI (1) SI2945967T1 (https=)
WO (2) WO2014111744A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013373679A1 (en) 2013-01-16 2015-08-13 Inserm (Institut National De La Sante Et De La Recherche Medicale) A soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
US20180148494A1 (en) 2015-01-07 2018-05-31 TheAchon Soluble fgfr3 decoys for treating skeletal growth disorders
KR20170121719A (ko) * 2016-04-25 2017-11-02 장부다 Vr 공간에서 사용자 인터페이스를 제공하는 방법, 디바이스 및 기록매체
PT3481859T (pt) 2016-07-07 2022-05-23 Pfizer Polipéptidos do recetor 3 do fator de crescimento dos fibroblastos (sfgfr3) solúveis e utilizações dos mesmos
JP7335247B2 (ja) * 2017-09-20 2023-08-29 ファイザー・インク 可溶性線維芽細胞増殖因子受容体３（ｓＦＧＦＲ３）ポリペプチドを使用した異常内臓脂肪蓄積の処置
CN108410803B (zh) * 2018-03-28 2019-02-05 湖南源品细胞生物科技有限公司 一种诱导脂肪干细胞成软骨分化的培养方法和培养液
CN110272900B (zh) * 2019-04-19 2024-03-26 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
WO2022254319A1 (en) 2021-06-01 2022-12-08 Pfizer Inc. Cell culture method for producing sfgfr3 polypeptide

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11508358A (ja) * 1995-06-12 1999-07-21 イエーダ リサーチ アンド ディベロップメント カンパニー，リミテッド 間葉性骨格前駆細胞についてのマーカーとしてのｆｇｆｒ３
JP2003104908A (ja) * 2001-09-28 2003-04-09 Ichikazu Nakao 軟骨無形成症治療剤
JP2003113116A (ja) * 2001-10-05 2003-04-18 Ichikazu Nakao 軟骨無形成症治療剤
WO2004110487A1 (en) * 2003-06-17 2004-12-23 Prochon Biotech Ltd. Treatment of t cell mediated diseases by inhibition of fgfr3
JP2005500034A (ja) * 2001-06-20 2005-01-06 プロション バイオテク リミテッド 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
WO2007014123A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
JP2007526770A (ja) * 2004-02-24 2007-09-20 アラーガン、インコーポレイテッド ボツリヌス毒素スクリーニングアッセイ
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
WO2012088608A1 (en) * 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
EP2322644A1 (en) 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
CA2432257A1 (en) * 2000-12-18 2002-06-27 Gene Logic, Inc. Treatment of bone disorders by modulation of fgfr3
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
BRPI0203172B8 (pt) * 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
EP2046384A4 (en) 2006-06-15 2009-12-02 Fibron Ltd ANTIBODIES BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATION AND METHODS OF USING THE SAME
US8962556B2 (en) 2006-09-28 2015-02-24 Prochon Biotech Ltd. FGF-2 variants having N-terminal deletions and increased receptor selectivity and uses thereof
CL2007003411A1 (es) 2006-11-28 2008-07-04 Centelion Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
CN102171343B (zh) 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
TWI507205B (zh) 2009-03-25 2015-11-11 Genentech Inc 抗ｆｇｆｒ３抗體及使用方法
CN101585866B (zh) * 2009-07-02 2011-10-05 中国人民解放军第三军医大学野战外科研究所 调节fgfr3活性的多肽及其筛选方法和应用
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
AU2010319327B2 (en) 2009-11-13 2015-08-13 Five Prime Therapeutics, Inc. Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2
EP2512501A4 (en) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS
BR112012016992A2 (pt) 2010-01-14 2019-09-24 Univ Yale "funcionalidade que se liga a uma interface de contato assimétrico de um recpetor de tirosina quinase (rtk), hibridoma, composição farmacêutica, uso de uma quantidade efixaz da funcionalidade, método para identificar uma funcionalidade que se liga a uma interface de contato assimétrico de um receptor de tirosina quinase (rtk), e, molécula pequena".
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
AU2012328880B2 (en) 2011-10-24 2017-02-23 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
CN104797936B (zh) 2012-07-24 2017-11-24 纽约市哥伦比亚大学理事会 融合蛋白及其方法
CA2878183A1 (en) 2012-07-27 2014-01-30 Genentech, Inc. Methods of treating fgfr3 related conditions
CA2890346A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
AU2013373679A1 (en) 2013-01-16 2015-08-13 Inserm (Institut National De La Sante Et De La Recherche Medicale) A soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
PT3097122T (pt) 2014-01-24 2020-07-21 Ngm Biopharmaceuticals Inc Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
US20180148494A1 (en) 2015-01-07 2018-05-31 TheAchon Soluble fgfr3 decoys for treating skeletal growth disorders
PT3481859T (pt) 2016-07-07 2022-05-23 Pfizer Polipéptidos do recetor 3 do fator de crescimento dos fibroblastos (sfgfr3) solúveis e utilizações dos mesmos
JP7335247B2 (ja) 2017-09-20 2023-08-29 ファイザー・インク 可溶性線維芽細胞増殖因子受容体３（ｓＦＧＦＲ３）ポリペプチドを使用した異常内臓脂肪蓄積の処置

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11508358A (ja) * 1995-06-12 1999-07-21 イエーダ リサーチ アンド ディベロップメント カンパニー，リミテッド 間葉性骨格前駆細胞についてのマーカーとしてのｆｇｆｒ３
JP2005500034A (ja) * 2001-06-20 2005-01-06 プロション バイオテク リミテッド 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
JP2003104908A (ja) * 2001-09-28 2003-04-09 Ichikazu Nakao 軟骨無形成症治療剤
JP2003113116A (ja) * 2001-10-05 2003-04-18 Ichikazu Nakao 軟骨無形成症治療剤
WO2004110487A1 (en) * 2003-06-17 2004-12-23 Prochon Biotech Ltd. Treatment of t cell mediated diseases by inhibition of fgfr3
JP2007526770A (ja) * 2004-02-24 2007-09-20 アラーガン、インコーポレイテッド ボツリヌス毒素スクリーニングアッセイ
WO2007014123A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
WO2012088608A1 (en) * 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARCHIVES DE PEDIATRIE, vol. 16, no. 6, JPN5016001787, 1 June 2009 (2009-06-01), pages 664 - 666, ISSN: 0003832908 *
BRITISH JOURNAL OF CANCER, vol. 89, no. 7, JPN5016001599, 2003, pages 1276 - 1284, ISSN: 0003451511 *
HUMAN MOLECULAR GENETICS, vol. 21, no. 26, JPN5016001597, December 2012 (2012-12-01), pages 5443 - 5455, ISSN: 0003451509 *
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 27, JPN5016001598, 2010, pages 20644 - 20653, ISSN: 0003451510 *

Also Published As

Publication number Publication date
AU2013373679A1 (en) 2015-08-13
JP6995069B2 (ja) 2022-02-04
PE20151664A1 (es) 2015-11-28
EA201591055A1 (ru) 2016-04-29
US11702642B2 (en) 2023-07-18
KR20150122136A (ko) 2015-10-30
US20210032608A1 (en) 2021-02-04
JP2016506912A (ja) 2016-03-07
WO2014111467A1 (en) 2014-07-24
US11814654B2 (en) 2023-11-14
DK2945967T3 (da) 2020-07-13
CA2896978A1 (en) 2014-07-24
EP2945967A1 (en) 2015-11-25
ES2796743T3 (es) 2020-11-30
KR20210054026A (ko) 2021-05-12
CN105121464A (zh) 2015-12-02
MX372787B (es) 2020-07-03
WO2014111744A1 (en) 2014-07-24
SG11201505140XA (en) 2015-07-30
MX2015009142A (es) 2015-11-06
US10724014B2 (en) 2020-07-28
KR102249454B1 (ko) 2021-05-07
EA201591324A1 (ru) 2016-01-29
CN105121464B (zh) 2021-05-07
US20150344855A1 (en) 2015-12-03
AU2014206844A1 (en) 2015-07-16
IL239810A0 (en) 2015-08-31
US20200199545A1 (en) 2020-06-25
HK1217959A1 (zh) 2017-01-27
SG11201505488XA (en) 2015-08-28
IL239996A0 (en) 2015-08-31
US20150353624A1 (en) 2015-12-10
PL2945967T3 (pl) 2020-11-16
MX2019013857A (es) 2020-01-20
EP2945967B1 (en) 2020-04-15
HUE049556T2 (hu) 2020-09-28
CA2898415A1 (en) 2014-07-24
US20210032607A1 (en) 2021-02-04
KR20160002681A (ko) 2016-01-08
JP2019107006A (ja) 2019-07-04
SI2945967T1 (sl) 2020-10-30
EP3736285A1 (en) 2020-11-11
PT2945967T (pt) 2020-05-28

Similar Documents

Publication Publication Date Title
JP6995069B2 (ja) 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
RS53302B (sr) Alkalna fosfataza koja je usmerena na kosti, pribor i postupci upotrebe
EP3308796A1 (en) Activin-actrii antagonists and uses for treating bone and other disorders
EP3242888B1 (en) Solube fgfr3 decoys for treating skeletal growth disorders
JP2022003048A (ja) 組織石灰化の治療方法
US20200297799A1 (en) Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides
JP2020015733A (ja) 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
HK40039498A (en) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
HK1217959B (en) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
HK40050674A (en) Soluble fgfr3 decoys for treating skeletal growth disorders
HK1246313B (en) Soluble fgfr3 decoys for treating skeletal growth disorders

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20151001

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20150716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160926

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180314

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180517

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20180706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190520

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190828